Aethlon Medical, Inc. (AEMD)

Market Cap	4.01M
Revenue (ttm)	574,245
Net Income (ttm)	-12.25M
Shares Out	2.62M
EPS (ttm)	-5.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	602
Open	1.510
Previous Close	1.530
Day's Range	1.510 - 1.530
52-Week Range	1.350 - 5.000
Beta	1.94
Analysts	Strong Buy
Price Target	10.00 (+553.6%)
Earnings Date	Feb 14, 2024

About AEMD

Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. The company was founded in 1999 and is based in San Diego, California.

• Industry: Medical Devices
• Sector: Healthcare
• CEO: James B. Frakes M.B.A.
• Employees: 15
• Stock Exchange: NASDAQ
• Ticker Symbol: AEMD

Financial Performance

In 2022, AEMD's revenue was $574,245, an increase of 95.21% compared to the previous year's $294,165. Losses were -$12.03 million, 15.5% more than in 2021.

Analyst Forecast

According to one analyst, the rating for AEMD stock is "Strong Buy" and the 12-month stock price forecast is $10.0.

Price Target

$10.0

(553.60% upside)

Analyst Consensus: Strong Buy